Cargando…
Nanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy
Ang-(1-9) peptide is a bioactive vasodilator peptide that prevents cardiomyocyte hypertrophy in vitro and in vivo as well as lowers blood pressure and pathological cardiovascular remodeling; however, it has a reduced half-life in circulation, requiring a suitable carrier for its delivery. In this wo...
Autores principales: | Sepúlveda-Rivas, Sabrina, Leal, Matías S., Pedrozo, Zully, Kogan, Marcelo J., Ocaranza, María Paz, Morales, Javier O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228229/ https://www.ncbi.nlm.nih.gov/pubmed/34206106 http://dx.doi.org/10.3390/pharmaceutics13060822 |
Ejemplares similares
-
Polycystin-1 is required for insulin-like growth factor 1-induced cardiomyocyte hypertrophy
por: Fernández, Carolina, et al.
Publicado: (2021) -
Communication Between Cardiomyocytes and Fibroblasts During Cardiac Ischemia/Reperfusion and Remodeling: Roles of TGF-β, CTGF, the Renin Angiotensin Axis, and Non-coding RNA Molecules
por: Flores-Vergara, Raúl, et al.
Publicado: (2021) -
Herpud1 negatively regulates pathological cardiac hypertrophy by inducing IP3 receptor degradation
por: Torrealba, Natalia, et al.
Publicado: (2017) -
Adenoviral Delivery of Angiotensin-(1-7) or Angiotensin-(1-9) Inhibits Cardiomyocyte Hypertrophy via the Mas or Angiotensin Type 2 Receptor
por: Flores-Muñoz, Monica, et al.
Publicado: (2012) -
Development of Novel EE/Alginate Polyelectrolyte Complex Nanoparticles for Lysozyme Delivery: Physicochemical Properties and In Vitro Safety
por: Sepúlveda-Rivas, Sabrina, et al.
Publicado: (2019)